Corporate Report: Mergers Orders and Undertakings Register

Why It Matters

The register offers transparent insight into how competition authorities shape merger outcomes, helping businesses and investors gauge regulatory risk and compliance obligations. Its accessibility strengthens market confidence and informs strategic M&A planning.

Key Takeaways

• Register tracks EA02 and FTA73 merger remedies and undertakings.
• Latest update added Schlumberger, ChampionX, Safran, Topps Tiles entries.
• Over 30 updates since 2022 show active regulatory monitoring.
• Transparency aids investors assessing M&A risk and compliance costs.
• Government maintains public access to remedy status for market confidence.

Pulse Analysis

The Competition and Markets Authority’s public register serves as a cornerstone of the United Kingdom’s merger control regime. By cataloguing orders and undertakings issued under the Enterprise Act 2002 and the Fair Trading Act 1973, the CMA provides a single source of truth for regulators, lawyers, and corporate strategists. The register’s structure—separating remedies in force from lapsed or interim measures—allows stakeholders to track the lifecycle of competition commitments and understand the conditions attached to high‑profile deals.

Recent updates illustrate the register’s relevance to today’s M&A landscape. Entries added in 2025 and 2026 include remedies for Schlumberger Limited’s acquisition of ChampionX, Safran S.A.’s transactions, and Topps Tiles PLC, reflecting the CMA’s focus on sectors ranging from industrial equipment to consumer goods. The frequency of revisions—more than thirty since early 2022—signals an increasingly proactive stance by the authority, as it seeks to address complex cross‑border deals and emerging market dynamics. Each amendment is publicly posted, ensuring that competitors and investors can monitor how competition concerns are being mitigated.

For businesses, the register is more than a compliance checklist; it is a strategic intelligence tool. Transparent access to remedy details helps companies forecast potential divestiture costs, assess the feasibility of proposed synergies, and negotiate more effectively with regulators. Investors can incorporate the likelihood of remedial actions into valuation models, reducing surprise post‑deal expenses. As the CMA continues to refine its merger oversight, the public register will remain a vital resource for fostering confidence in the UK market and guiding informed M&A decisions.